HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bausch Sees Sales Drivers In Lumify, Ocuvite And PreserVision Line Extensions

Executive Summary

Lumify reached 35% market share in US OTC eye drops and Ocuvite and Preservision vision health supplements are the No. 2 sales driver across Bausch's total portfolio.

You may also be interested in...



Bausch Expects US Approval In 2020 Of Preservative-Free OTC Ketotifen Eye Drop

Bausch says it expects US FDA to approve its ANDA for the first preservative-free OTC eye drop for ocular itching associated with allergic conjunctivitis in the second half of 2020. The firm reports its Lumify redness relief drops generated sales of $63m for 2019.

Bausch's Lumify Eye Drops Sales Jump To Double Competitors' Market Share

Lumify redness relief eye drops nearly doubled in sales between Bausch's second and third quarters and drove 7% organic growth of its global consumer business compared to the year-ago period. The brand has double the market share of its two closest competitors, and the firm plans clinical studies for product extensions to the brand in 2020.

Wellness Market News: Abbott Nutrition Q3 Up 1.6%, Easier-To-Swallow PreserVision AREDS, More

Ensure, Glucerna brands boost Abbott Nutrition adult product third-quarter sales 3.9% on reported basis to $830m; Baush + Lomb relaunches PreserVision AREDS 2 Formula soft gels with easier-to-swallow option; Hum Nutrition Mighty Night supplement boosts skin cell renewal during sleep; and NOW Health Group acquires family-owned SuperNutrition.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel